Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) EBITDA (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed EBITDA for 16 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 243.64% to $13.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.0 million through Dec 2025, up 281.38% year-over-year, with the annual reading at $41.0 million for FY2025, 281.38% up from the prior year.
  • EBITDA hit $13.8 million in Q4 2025 for Ligand Pharmaceuticals, down from $54.9 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $54.9 million in Q3 2025 to a low of -$36.2 million in Q1 2025.
  • Historically, EBITDA has averaged $6.9 million across 5 years, with a median of $3.9 million in 2021.
  • Biggest YoY gain for EBITDA was 1647.73% in 2025; the steepest drop was 1312.05% in 2025.
  • Year by year, EBITDA stood at $37.7 million in 2021, then crashed by 153.33% to -$20.1 million in 2022, then soared by 83.29% to -$3.4 million in 2023, then plummeted by 186.99% to -$9.6 million in 2024, then skyrocketed by 243.64% to $13.8 million in 2025.
  • Business Quant data shows EBITDA for LGNDZ at $13.8 million in Q4 2025, $54.9 million in Q3 2025, and $8.4 million in Q2 2025.